TR10: Dual-Action Antibodies
At Genentech, one of this year’s TR10 innovators, Germaine Fuh is developing a new variety of drug that can target more than one type of molecule, potentially reducing costs and simplifying treatment. We asked Fuh how it worked and what it might mean for patients.
Keep Reading
Most Popular
Anti-aging drugs are being tested as a way to treat covid
Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.
These materials were meant to revolutionize the solar industry. Why hasn’t it happened?
Perovskites are promising, but real-world conditions have held them back.
The baby formula shortage has birthed a shady online marketplace
Desperate parents just want to feed their babies. They’re having to contend with misinformation, price gouging, and scams along the way.
I tried to buy an Olive Garden NFT. All I got was heartburn.
Our newest issue spells out what you need to know about the dizzying world of digital money.
Stay connected
Illustration by Rose WongGet the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.